mirvetuximab soravtansine
Trade name: Elahere
mAbapprovedADCOrphan Drug FDAFast Track FDA
Approved
Nov 14, 2022
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. — Wikipedia
Clinical trial activity
25 trials · 24 clinical orgs · 1 marketing orgs
Phase 1
7
Phase 2
19
Phase 3
6
Phase 4
0
Earliest trial started May 1, 2012 (NCT01609556)
Timeline
2010s
Indications
Approved for
Studied for
- Biomarkers · Phase 2
- BRCA1 Protein · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 3
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 3
- Fallopian Tubes · Phase 2
- Folate Receptor 1 · Phase 3
- Hamartoma · Phase 3
- Mutation · Phase 1
- Neoadjuvant Therapy · Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 3
- Peritoneal Cavity · Phase 3
- Platinum · Phase 3
- Uterine Neoplasms · Phase 1
Mechanism of action
- Folate receptor alphaBINDING AGENT
FOLR1 binding agent
- Folate receptor alphaINHIBITOR
FOLR1 inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Approval history
- approvedPriority reviewAcceleratedFast trackNov 14, 2022
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
- Payload
- Ravtansine
Oral
No
Parenteral
Yes
Topical
No
Black box warningFirst in class
Sources
- WikipediaImmunoGen ↗
- ChEMBLCHEMBL3545132 ↗
- ChEMBLCHEMBL2109414 ↗
Also known as
- imgn853
- imgn853
- imgn853
- imgn-853
- mirvetuximab soravtansine
- mirvetuximab soravtansine
- mirvetuximab soravtansine
- mirvetuximab soravtansine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07218809 | Phase 3 | Nov 28, 2025 | AstraZeneca, European Network for Gynaecological Oncological Trial, GOG Foundation, Inc. |
| NCT06890338 | Phase 2 | Nov 21, 2025 | AbbVie, GOG Foundation, Inc. |
| NCT07059845 | Phase 2 | Nov 13, 2025 | AbbVie |
| NCT06682988 | Phase 3 | Feb 6, 2025 | AbbVie |
| NCT06365853 | Phase 2 | Jul 29, 2024 | AbbVie |
| NCT06390995 | Phase 1/Phase 2 (Phase 2) | May 20, 2024 | Takeda |
| NCT05887609 | Phase 2 | Oct 3, 2023 | Immunogen, University of Colorado, Denver |
| NCT05456685 | Phase 2 | Sep 28, 2022 | AbbVie, Immunogen |
| NCT05622890 | Phase 3 | Aug 18, 2022 | Hangzhou Zhongmei |
| NCT05483933 | Phase 1 | Aug 18, 2022 | Shattuck Labs |
| NCT05041257 | Phase 2 | Aug 31, 2021 | Immunogen, IQVIA |
| NCT04606914 | Phase 2 | May 27, 2021 | University of Alabama, Birmingham |
| NCT04274426 | Phase 2 | Jul 31, 2020 | AGO Germany |
| NCT04296890 | Phase 3 | Apr 30, 2020 | Immunogen, IQVIA |
| NCT04209855 | Phase 3 | Dec 31, 2019 | Gynecologic Oncology Group, Immunogen |
| NCT03832361 | Phase 2 | Aug 31, 2019 | Immunogen, Yale University |
| NCT03836157 | Phase 2 | May 31, 2019 | Immunogen, University of Oklahoma |
| NCT03835819 | Phase 2 | Mar 31, 2019 | Harvard University, Immunogen, Merck |
| NCT03552471 | Phase 1 | Jul 12, 2018 | Clovis Oncology, Immunogen, Ohio State University |
| NCT03106077 | Phase 2 | Jun 5, 2017 | National Comprehensive Cancer Network, University of Texas at Houston |
Showing 20 of 25 trials
Page 1 / 2
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunogen | For profit | 12 | 7 | 3 | 2012 |
| AbbVie | For profit | 5 | 5 | 2 | 2022 |
| GOG Foundation, Inc. | Academic/Hospital | 2 | 0 | 2 | 2025 |
| Gynecologic Oncology Group | Academic/Hospital | 2 | 0 | 1 | 2016 |
| IQVIA | For profit | 2 | 0 | 2 | 2020 |
| National Comprehensive Cancer Network | Academic/Hospital | 2 | 0 | 2 | 2017 |
| AGO Germany | Academic/Hospital | 1 | 1 | 1 | 2020 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2025 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Clovis Oncology | For profit | 1 | 0 | 1 | 2018 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Hangzhou Zhongmei | For profit | 1 | 1 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Shattuck Labs | For profit | 1 | 1 | 1 | 2022 |
| Takeda | For profit | 1 | 1 | 1 | 2024 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2021 |
24 organizations
Page 1 / 2